Analyst consensus rating
Teva Pharmaceutical Industries Analyst Rating: Strong Buy
TEVA is rated Strong Buy by 10 analysts with a $41.40 target. As of 2026-08-21.
Direct answer
Teva Pharmaceutical Industries's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $41.40.
Forecast evidence checked August 21, 2026.
Get free Teva Pharmaceutical Industries email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $36.81
- Average price target
- $41.40
- High price target
- $50.00
- Low price target
- $33.00
- Low target gap
- -10.4%
- Target upside
- +12.5%
- High target gap
- +35.8%
- Target range width
- 46.2%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a verified Strong Buy consensus. The same dataset has an average price target of $41.40.
How far are Teva Pharmaceutical Industries's low and high targets from the recorded price?
The low target implies -10.4%, while the high target implies +35.8%.
How many analysts are included in Teva Pharmaceutical Industries's consensus?
The verified consensus includes 10 analysts.
How is Teva Pharmaceutical Industries's target upside or downside calculated?
The average target of $41.40 is divided by the recorded price of $36.81, then one is subtracted to produce +12.5%. This does not guarantee a future return.
When was Teva Pharmaceutical Industries's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.